Incyte Stock News

These two companies offer products that are always in demand, regardless of economic conditions.

Incyte: All Atention On Opzelura

The recent pipeline setbacks will weigh on Incyte's (INCY) growth trajectory and jeopardize its plans to diversify its revenue base.

Incyte' s (INCY) sNDA seeking label expansion of ruxolitinib cream gets extended by three months by the FDA for reviewing additional information.

The U.S. Food and Drug Administration extended the review period by three months for Incyte''s (INCY) application seeking extended approval of ruxolitinib cream (Opzelura) to…

The FDA has extended the review period for Incyte Corporation''s (NASDAQ: INCY ) supplemental application for ruxolitinib cream (Opzelura) for vitiligo. The Prescription Drug User Fee Act (PDUFA) action date has been extended by three months to July 18 from April 18 . The FDA … Full story available on Benzinga.com

Although US stock futures traded higher this morning on Friday, there were a few notable insider trades. When insiders purchase shares, it indicates their confidence in the company's prospects or that

Most investors are likely familiar with the adage, "actions speak louder than words." That saying certainly applies to the executives and other corporate insiders buying and selling shares of their own company''s stock. It''s part of an executive''s job to paint a rosy public picture of the future of a company, but a CEO''s bullish words may not be an accurate reflection of how he or she truly feels about a stock. However, if company insiders are backing up positive words with insider buying, it can be a confirming indication that management is truly bullish enough about the future to put their own skin in the game. Here are seven stocks that Bank of America analysts recommend that have seen insider ownership increase in the last year. Incyte Corporation (NASDAQ: INCY ) Incyte develops and commercializes oncology therapies. Analyst Tazeen Ahmad says Jakafi, a medication used to treat certain bone marrow disorders, and additional revenue streams provide a floor under Incyte''s valuation, and the company''s late-stage dermatology program could be a near-term growth catalyst.

Most investors are likely familiar with the adage, "actions speak louder than words." That saying certainly applies to the executives and other corporate insiders buying and selling shares of their ow

A new study found that baricitinib, a rheumatoid arthritis drug developed by Eli Lilly & Co. and Incyte Corp. , reduced the risk of death among patients who have been hospitalized with severe COVID-19. The new research, which was published Thursday in preprint form, meaning it''s not peer-reviewed, came from the U.K.''s Recovery Trial. It compared baricitinib and the standard of care with the standard of care in about 8,000 patients over the course of 2021. Roche Holding AG''s arthritis drug tocilizumab has also been found to be an effective tool to reduce mortality risk among some severely ill COVID-19 patients. Over the past year, Lilly''s stock has gained 28.4%, while Incyte shares are down 10.3%. The S&P 500 is up 14.2%. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

A U.K. study showed that Eli Lilly (LLY) Incyte''s (INCY) Olumiant (baricitinib) helped reduce the risk of death in patients with COVID-19 patients who were hospitalized by 13% regardless…

Eli Lilly and Incyte''s arthritis drug baricitinib helped reduce the risk of death in hospitalised COVID-19 patients by 13per cent regardless of which other coronavirus treatment they were given, according to a large British study. Over 8,000 patients were administered baricitinib in addition to usual care,

According to a British study, Eli Lilly And Co (NYSE: LLY ) and Incyte Corporation''s (NASDAQ: INCY ) Olumiant (baricitinib) reduced the risk of death in hospitalized COVID-19 patients by 13%. According to a Reuters report , more than 8,000 patients were administered baricitinib in addition to standard of care in the RECOVERY Trial. Results showed that 546 patients in the standard … Full story available on Benzinga.com

(Reuters) -CTI BioPharma Corp said on Monday the U.S. Food and Drug Administration has approved its drug for treating adult patients with a type of bone marrow cancer who also have low blood platelet count. The drug, Vonjo (pacritinib), belongs to a class of anti-inflammatory treatments called JAK inhibitors, and will compete with Incyte Corp’s […]

The FDA approved CTI BioPharma Corp''s (NASDAQ: CTIC ) Vonjo (pacritinib) for treating adult patients with myelofibrosis, a type of bone marrow cancer with low blood platelets count. Pacritinib is a JAK inhibitor and will compete with Incyte Corporation''s (NASDAQ: INCY ) Jakafi and Bristol Myers Squibb''s Co (NYSE: BMY ) Inrebic, which were approved in 2011 and 2019, respectively for myelofibrosis. CTI BioPharma Chief Executive Officer Adam R. Craig said, "We are … Full story available on Benzinga.com